Hansa Biopharma announces positive early access decision by French Haute Autorité de Santé to use Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients

/PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announces that...

Related Keywords

Sweden ,Germany ,Stockholm ,Netherlands ,United Kingdom ,Italy ,Finland ,France ,Spain ,Jordan ,Greece ,French ,Hansa Biopharma ,Klaus Sindahl ,Katja Margell ,Transparency Commission ,National Security System ,European Union ,European Medicines Agency ,European Medicines Agency Ema Priority ,A Health Technology Assessment ,French Public Health Code ,Head Of Corporate Communications ,Nasdaq Stockholm ,Haute Autorit ,Marketing Authorization ,Agence De Biom ,Health Technology Assessment ,Human Leukocyte Antigens ,European Marketing Authorization ,End Stage Renal Disease ,Product Characteristicsfound ,Product Characteristics ,Englj Med ,Hansa Biopharma Ab ,